RECURSION PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year Three
RECURSION PHARMACEUTICALS, INC. (RXRX) had Long-Term Debt, Maturity, Year Three of $105.00 thousand as of 2021-12-31, per its 10-K filed 2022-03-23.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2022-03-23
- 2021-12-31: Long-Term Debt, Maturity, Year Three $105.00K.
- 2021-09-30: Long-Term Debt, Maturity, Year Three $105.00K.
- 2021-06-30: Long-Term Debt, Maturity, Year Three $3.06M.
- 2021-03-31: Long-Term Debt, Maturity, Year Three $3.06M.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2021-12-31 | $105.00K 10-K · filed 2022-03-23 |
| 2021-09-30 | $105.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $3.06M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $3.06M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |